• All Products
  • By Generic
  • By Therapeutic Segment


Therapeutic Segment: Oncology

Generic Name: Trastuzumab


Trastuget (Trastuzumab) is indicated for:

Adjuvant Breast Cancer
Trastuget (Trastuzumab) is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer:
• as part of a treatment regimen consisting of doxorubicin, clophosphamide, and either paclitaxel or docetaxel.
• as part of a treatment regimen with docetaxel and carboplatin.
• as a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Metastatic Gastric Cancer
• in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.

Available as:

  • 440MG

Buy our products online.

Making lives easier, healthier, happier.

Click to Order Online